Companies › Trellis Bioscience
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRL1068 (calpurbatug) Human monoclonal antibody targeting biofilm in prosthetic joint infections | – | Phase 2 | Prosthetic Joint Infections of Hip | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06621251 | TRL1068 (calpurbatug) | Phase 2 | Prosthetic Joint Infections of Hip | Infectious disease | Apr 2027 |
No annotated target.
–
Zura Bio Amplexd Therapeutics Biothervax Sano Chemicals Hyundai Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.